Oroxine 175 mikrogram tabletter דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

oroxine 175 mikrogram tabletter

aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 175 mikrogram

Oroxine 200 mikrogram tabletter דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

oroxine 200 mikrogram tabletter

aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 200 mikrogram

Oroxine 25 mikrogram tabletter דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

oroxine 25 mikrogram tabletter

aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 25 mikrogram

Oroxine 50 mikrogram tabletter דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

oroxine 50 mikrogram tabletter

aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 50 mikrogram

Oroxine 75 mikrogram tabletter דנמרק - דנית - Lægemiddelstyrelsen (Danish Medicines Agency)

oroxine 75 mikrogram tabletter

aspen pharma trading ltd. - levothyroxinnatrium - tabletter - 75 mikrogram

Lytgobi האיחוד האירופי - דנית - EMA (European Medicines Agency)

lytgobi

taiho pharma netherlands b.v. - futibatinib - cholangiocarcinoma - antineoplastiske midler - lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.